AIDS Therapies (HIV-IG)

Trial Continues Following Interim Efficacy Review

Published in AIDS Weekly, February 3rd, 1997

NABI, Boca Raton, Florida, announced that the U.S. National Institutes of Health (NIH) will continue the Phase III trial of HIV-IG, following an interim efficacy review made by an independent Data and Safety Monitoring Board (DSMB).

The DSMB is continuing in session to review additional data over the coming weeks. No safety problems were reported in the interim review. HIV-IG is NABI's immunotherapeutic product in development for the prevention of HIV transmission from mother to infant and is currently in a Phase III randomized, double-blind, controlled study.

To date, 459 mothers have been enrolled in the study, and 432 babies have been born to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry